Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus
Conditions
Interventions
hydroxychloroquine in combination with camostat mesylate
Hydroxychloroquine in combination of Azithromycin
Locations
2
Israel
Sheba Medical Center
Ramat Gan, Israel
Sheba Medical Center
Tel Litwinsky, Israel
Start Date
April 11, 2020
Primary Completion Date
October 11, 2020
Completion Date
December 11, 2020
Last Updated
April 21, 2020
NCT07190131
NCT06831786
NCT07190911
NCT07134725
NCT07126392
NCT07118917
Lead Sponsor
Sheba Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions